Date and Time:  4 February 2015 10:00 – 16:00

Minutes: DRAFT

Guideline Development Group Meeting

Place:  The Linacre Room, Royal College of Physicians, 11 St. Andrews Place, Regent’s Park, London, NW1 4LE

Present:  

Guideline Development Group
Bruce Guthrie  (Chair) BG
Alaster Rutherford  (Pharmacist) AR
Andrew Clegg  (Geriatrician) AC
Carolyn Chew-Graham  (General Practitioner) CCG
Cate Seton-Jones  (Palliative Care Specialist) CSJ
David Kernick  (General Practitioner) DK
Emily Lam  (Lay member) EL
Jonathan Inglesfield  (General Practitioner) JI
John Hindle  (Geriatrician) JH
Julia Botsford  (Psychiatrist CPN) JB
Nina Barnett  (Pharmacist) NB
Rupert Payne  (General Practitioner) RP
Sam Barnett-Cormack  (Lay member) SBC

National Clinical Guidelines Centre
Norma O’Flynn  (Guideline Lead/Clinical Director) NOF
Emma Madden  (Research Fellow) EM
Joanna Ashe  (Senior Information Scientist) JA
Kate Lovibond  (Senior Health Economist) KL
Sharon Swain  (Senior Research Fellow) SS
Sophia Kemmis-Betty  (Health Economist) SKB
Tamara Diaz  (Project Manager) TD
Lindsay Dytham  (Document Editor / Process Assistant) LD

In attendance:

NICE Staff
Caroline Keir  (Guidelines Commissioning Manager) CK

Apologies:

None
Notes

1. BG welcomed the group to the second meeting of this GDG. There were no apologies for this meeting.

2. The Chair asked all GDG members to declare any relevant conflicts of interest. The following DOIs were noted:
   
   AC declared that he is currently leading work to develop and validate a frailty index based on routine primary care data. This work is funded by the NIHR (National Institute for Health Research) CLAHREC (The Collaboration for Leadership in Applied Health Research and Care) Programme. It was agreed that this declaration did not present a conflict for items on the day’s agenda as the group would not be asked to consider evidence or draft recommendations on the topic.

3. Definition: Multimorbidity
   The group continued discussions on their understanding of the term multimorbidity and how it might be interpreted in the guideline.

4. Protocols and review questions:
   SS presented the draft protocols for reviews on:
   
   - **Format of Consultations**
     What format(s) of consultations with healthcare professionals improve outcomes for people with multimorbidity?
   
   - **Continuity of Care**
     What is the clinical and cost effectiveness of strategies to improve continuity of healthcare, for example care plans, case management and named health professionals to improve outcomes for people with multimorbidity?
   
   - **Self-Management**
     What is the clinical and cost effectiveness of self-management and expert patient programmes in improving outcomes for people with multimorbidity?

   The protocols were refined through discussions of the GDG.

5. Evidence review
   SS and EM presented evidence on the effect of stopping treatment with anti-hypertensives for primary and secondary prevention. The GDG discussed the evidence presented.

Date, time and venue of the next meeting

17 March 2015, 10:00-16:00 at the Boardroom, NCGC, 180 Great Portland Street, London, W1W 5QZ.